Cellares and GenomeFrontier plan automated GF-CART01 production
The partners will assess automated manufacture of GenomeFrontier's virus-free CAR T process; the collaboration is Cellares' first with an Asian cell-therapy developer. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
- Published by
- GEN — Genetic Engineering & Biotechnology News
- Evidence type
- Industry
GEN reports: The partners will assess automated manufacture of GenomeFrontier's virus-free CAR T process; the collaboration is Cellares' first with an Asian cell-therapy developer.
The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance. Consult the linked GEN report for the source organisation’s full announcement.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.
Prefer to talk it through? Book a 30-minute discovery call